Assembly Biosciences to Present at Herpesvirus Workshop and EASL Congress 2024

Assembly Biosciences, Inc., a biotech firm specializing in developing novel treatments for viral diseases, has announced its upcoming presentations of preclinical data at key medical conferences. The data is focused on their herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs.

At the International Herpesvirus Workshop, scheduled to be held in Portland, Oregon from July 13-17, 2024, Assembly Bio will share findings on their long-acting helicase-primase inhibitor candidates, ABI-5366 and ABI-1179, designed for treating recurrent genital herpes. ABI-5366 will be featured in a poster presentation, while ABI-1179 will be highlighted in both an oral and a poster presentation.

William Delaney, PhD, the chief scientific officer at Assembly Bio, expressed enthusiasm about presenting these promising HSV inhibitors. He emphasized the need for improved treatments, noting that current therapies only partially control recurrences. Delaney pointed out that Assembly Bio’s approach targets the viral helicase-primase complex, a different mechanism from existing treatments, and that the company is on track to begin clinical trials for ABI-5366 by mid-year and ABI-1179 by the end of the year.

Presentation details at the International Herpesvirus Workshop are as follows:

ABI-5366
- Poster Presentation: "The Helicase-Primase Inhibitor ABI-5366 is a Novel, Potent, Long-Acting Inhibitor for the Treatment of Recurrent Genital Herpes"
- Presenter: Ran Yan, PhD, Assembly Bio

ABI-1179
- Oral and Poster Presentation: "Preclinical Characterization of ABI-1179, a Potent Helicase-Primase Inhibitor for the Treatment of Recurrent Genital Herpes"
- Presenter: Heidi Contreras, PhD, Assembly Bio
- Oral Presentation Date and Time: July 16, 2024, at 11:00 AM PDT

Moreover, the European Association for the Study of the Liver (EASL) Congress 2024, to be held in Milan, Italy from June 5-8, 2024, will feature Assembly Bio’s data on ABI-6250. ABI-6250 is a novel, orally bioavailable entry inhibitor candidate for treating chronic HDV. The preclinical profile of ABI-6250 underscores its potential to offer new therapeutic options for individuals with chronic HDV, a severe form of viral hepatitis that often leads to cirrhosis within a decade. Dr. Anuj Gaggar, the chief medical officer at Assembly Bio, highlighted the limitations of current HDV treatments, which are mainly available in Europe and require daily injections. He noted that ABI-6250 aims to provide a more convenient, once-daily oral treatment, with clinical trials expected to commence by the end of the year.

Presentation details at the EASL Congress are as follows:

ABI-6250
- Poster WED-377: "Preclinical profiling of ABI-6250, a novel orally bioavailable small-molecule therapeutic candidate for the treatment of chronic hepatitis D"
- Presenter: Marc P. Windisch, PhD, Assembly Bio
- Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
- Date and Time: June 5, 2024, 8:30 AM-6:00 PM

The investigational products discussed, ABI-5366, ABI-1179, and ABI-6250, have not been approved anywhere globally, and their safety and efficacy are yet to be established. Assembly Biosciences is committed to developing innovative small-molecule therapeutics aimed at improving the lives of patients affected by serious viral diseases, specifically herpesvirus, hepatitis B virus (HBV), and hepatitis delta virus (HDV) infections.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!